- Home
- HBIO vs CUE Comparison
HBIO vs CUE Comparison
Compare HBIO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBIO
- CUE
- Stock Information
- Founded
- HBIO 1901
- CUE 2014
- Country
- HBIO United States
- CUE United States
- Employees
- HBIO N/A
- CUE N/A
- Industry
- HBIO Biotechnology: Laboratory Analytical Instruments
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- HBIO Industrials
- CUE Health Care
- Exchange
- HBIO Nasdaq
- CUE Nasdaq
- Market Cap
- HBIO 61.2M
- CUE 60.6M
- IPO Year
- HBIO 2000
- CUE 2018
- Fundamental
- Price
- HBIO $0.60
- CUE $0.78
- Analyst Decision
- HBIO Buy
- CUE Strong Buy
- Analyst Count
- HBIO 1
- CUE 4
- Target Price
- HBIO $4.50
- CUE $4.75
- AVG Volume (30 Days)
- HBIO 366.5K
- CUE 145.1K
- Earning Date
- HBIO 03-12-2025
- CUE 05-08-2025
- Dividend Yield
- HBIO N/A
- CUE N/A
- EPS Growth
- HBIO N/A
- CUE N/A
- EPS
- HBIO N/A
- CUE N/A
- Revenue
- HBIO $94,135,000.00
- CUE $9,287,000.00
- Revenue This Year
- HBIO N/A
- CUE $13.61
- Revenue Next Year
- HBIO $7.97
- CUE $82.06
- P/E Ratio
- HBIO N/A
- CUE N/A
- Revenue Growth
- HBIO N/A
- CUE 69.16
- 52 Week Low
- HBIO $0.56
- CUE $0.45
- 52 Week High
- HBIO $4.70
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- HBIO 22.38
- CUE 27.21
- Support Level
- HBIO $0.56
- CUE $0.95
- Resistance Level
- HBIO $0.63
- CUE $1.05
- Average True Range (ATR)
- HBIO 0.06
- CUE 0.09
- MACD
- HBIO 0.02
- CUE -0.00
- Stochastic Oscillator
- HBIO 3.00
- CUE 5.42
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.